

*Status: Point in time view as at 16/04/2010.*

*Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part I. (See end of Document for details)*

## SCHEDULES

### SCHEDULE 2

#### CONTROLLED DRUGS

#### PART I

##### CLASS A DRUGS

- 1 The following substances and products, namely:—
- [<sup>F1</sup>(a)] Acetorphine.  
[<sup>F2</sup>Alfentanil.]  
Allylprodine.  
Alphacetylmethadol.  
Alphameprodine.  
Alphamethadol.  
Alphaprodine.  
Anileridine.  
Benzethidine.  
Benzylmorphine (3-benzylmorphine).  
Betacetylmethadol.  
Betameprodine.  
Betamethadol.  
Betaprodine.  
Bezitramide.  
Bufotenine.  
<sup>F3</sup> ...  
<sup>F4</sup> ...  
[<sup>F5</sup>Carfentanil.]  
Clonitazene.  
Coca leaf.  
Cocaine.  
Desomorphine.  
Dextromoramide.  
Diamorphine.  
Diampromide.  
Diethylthiambutene.  
[<sup>F6</sup>Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid).]  
Dihydrocodeinone *O*-carboxymethyloxime.

---

*Status: Point in time view as at 16/04/2010.*

*Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)*

---

[<sup>F7</sup>Dihydroetorphine]  
Dimenoxadole.  
Dimepheptanol.  
Dimethylthiambutene.  
Dioxaphetyl butyrate.  
Diphenoxylate.  
Dipipanone.  
[<sup>F8</sup>Drotebanol (3,4-dimethoxy-17-methylmorphinan-6b, 14-diol).]  
Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine.  
Ethylmethylthiambutene.  
[<sup>F2</sup>Eticyclidine.]  
Etonitazene.  
Etorphine.  
Etoxeridine.  
[<sup>F9</sup>Etryptamine]  
Fentanyl.  
[<sup>F10</sup>Fungus (of any kind) which contains psilocin or an ester of psilocin.]  
Furethidine.  
Hydrocodone.  
Hydromorphinol.  
Hydromorphone.  
Hydroxypethidine.  
Isomethadone.  
Ketobemidone.  
Levomethorphan.  
Levomoramide.  
Levophenacylmorphan.  
Levorphanol.  
[<sup>F5</sup>Lofentanil]  
Lysergamide.  
Lysergide and other *N*-alkyl derivatives of lysergamide.  
Mescaline.  
Metazocine.  
Methadone.  
Methadyl acetate.  
[<sup>F11</sup>Methylamphetamine]  
Methyldesorphine.  
Methyldihydromorphine (6-methyldihydromorphine).  
Metopon.  
Morpheridine.  
Morphine.  
Morphine methobromide, morphine *N*-oxide and other pentavalent nitrogen morphine derivatives.

---

*Status: Point in time view as at 16/04/2010.*

*Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)*

---

Myrophine.

<sup>F12</sup>  
. . .

Nicomorphine (3,6-dinicotinoylmorphine).

Noracymethadol.

Norlevorphanol.

Normethadone.

Normorphine.

Norpipanone.

Opium, whether raw, prepared or medicinal.

Oxycodone.

Oxymorphone.

Pethidine.

Phenadoxone.

Phenampromide.

Phenazocine.

[<sup>F13</sup>Phencyclidine.]

Phenomorphane.

Phenoperidine.

Piminodine.

Piritramide.

Poppy-straw and concentrate of poppy-straw.

Proheptazine.

Properidine (1-methyl-4-phenyl-piperidine-4-carboxylic acid  
isopropyl ester).

Psilocin.

Racemethorphan.

Racemoramide.

Racemorphan.

[<sup>F14</sup>Remifentanyl]

[<sup>F2</sup>Rolicyclidine.]

[<sup>F15</sup>Sufentanyl.]

[<sup>F2</sup>Tenocyclidine.]

Thebacon.

Thebaine.

[<sup>F15</sup>Tilidate.]

Trimeperidine.

[<sup>F16</sup>4-Bromo-2,5-dimethoxy- $\alpha$ -methylphenethylamine].

4-Cyano-2-dimethylamino-4,4-diphenylbutane.

4-Cyano-1-methyl-4-phenyl-piperidine.

*N,N*-Diethyltryptamine.

*N,N*-Dimethyltryptamine.

2,5-Dimethoxy- $\alpha$ ,4-dimethylphenethylamine.

[<sup>F17</sup>N-Hydroxy-tenamphetamine.]

1-Methyl-4-phenylpiperidine-4-carboxylic acid.

*Status: Point in time view as at 16/04/2010.*

*Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)*

- 2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid.  
 [<sup>F18</sup>4-Methyl-aminorex]  
 4-Phenylpiperidine-4-carboxylic acid ethyl ester.
- [<sup>F19</sup>(b) any compound (not being a compound for the time being specified in subparagraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- [ the following phenethylamine derivatives, namely:—
- <sup>F20</sup>(ba) Allyl( *a* -methyl-3,4-methylenedioxyphenethyl)amine  
 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol  
 2-Amino-1-(3,4-dimethoxyphenyl)ethanol  
 Benzyl( *a* -methyl-3,4-methylenedioxyphenethyl)amine  
 4-Bromo- *b* ,2,5-trimethoxyphenethylamine  
*N* -(4- *sec* -Butylthio-2,5-dimethoxyphenethyl)hydroxylamine  
 Cyclopropylmethyl( *a* -methyl-3,4-methylenedioxyphenethyl)amine  
 2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)ethylamine  
 2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)-1-methylethylamine  
 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine  
 2-(1,4-Dimethoxy-2-naphthyl)ethylamine  
 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine  
*N* -(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine  
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine  
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine  
*a* , *a* -Dimethyl-3,4-methylenedioxyphenethylamine  
*a* , *a* -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine  
 Dimethyl( *a* -methyl-3,4-methylenedioxyphenethyl)amine  
*N* -(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine  
 4-Iodo-2,5-dimethoxy- *a* -methylphenethyl(dimethyl)amine  
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine  
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine  
 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[ *b* ]furan-6-yl)-1-methylethylamine  
 2-Methoxyethyl( *a* -methyl-3,4-methylenedioxyphenethyl)amine  
 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[ *b* ]furan-6-yl)-1-methylethylamine  
*b* -Methoxy-3,4-methylenedioxyphenethylamine  
 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine  
 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine  
 2-( *a* -Methyl-3,4-methylenedioxyphenethylamino)ethanol  
*a* -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine  
*N* -Methyl- *N* -( *a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine

*Status: Point in time view as at 16/04/2010.*

*Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)*

- O* -Methyl- *N* -( *a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine  
*a* -Methyl-4-(methylthio)phenethylamine  
*b* ,3,4,5-Tetramethoxyphenethylamine  
*b* ,2,5-Trimethoxy-4-methylphenethylamine; ]
- (c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine an *N* -alkylphenethylamine, a-methylphenethylamine, an *N* -alkyl-a-methylphenethylamine, a-ethylphenethylamine, or an *N* -alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents. ]
- [<sup>F21</sup>(d) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from fentanyl by modification in any of the following ways, that is to say,
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
  - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
  - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
  - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
  - (v) by substitution at the 4-position of the piperidine ring with any alkoxy-carbonyl or alkoxyalkyl or acyloxy group;
  - (vi) by replacement of the N-propionyl group by another acyl group;
- (e) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from pethidine by modification in any of the following ways, that is to say,
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
  - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
  - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
  - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy-carbonyl or any alkoxyalkyl or acyloxy group;
  - (v) by formation of an N-oxide or of a quaternary base.]

#### Textual Amendments

- F1** "(a)" inserted by S.I. 1977/1243, **art. 3(a)**
- F2** Word inserted by S.I. 1984/859, **art. 2(2)**
- F3** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by *The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 2003 (S.I. 2003/3201)*, **art. 2(2)**
- F4** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by *The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 2003 (S.I. 2003/3201)*, **art. 2(2)**
- F5** Word inserted by S.I. 1986/2230, **art. 2(2)(a)**
- F6** Word inserted by S.I. 1975/421, **art. 3**

*Status: Point in time view as at 16/04/2010.*

*Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part I. (See end of Document for details)*

- F7** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003 /1243), art. 2(2)(a)
- F8** Word inserted by [S.I. 1973/771, art. 2](#)
- F9** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.5.1998) by [S.I. 1998/750, art. 2\(2\)](#)
- F10** Words in Sch. 2 Pt. 1 para. 1 inserted (18.7.2005) by [Drugs Act 2005 \(c. 17\), s. 21](#)
- F11** Word in Sch. 2 Pt. 1 para. 1(a) inserted (18.1.2007) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2006 \(S.I. 2006/3331\), art. 2\(1\)](#)
- F12** Words repealed by [S.I. 1973/771, art. 2](#)
- F13** Word inserted by [S.I. 1979/299, art. 2](#)
- F14** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003 /1243), art. 2(2)(b)
- F15** Word inserted by [S.I. 1983/765, art. 2\(a\)](#)
- F16** Words inserted by [S.I. 1975/421, art. 3](#)
- F17** Word inserted by [S.I. 1990/2589, art. 2\(a\)\(i\)](#)
- F18** Word inserted by [S.I. 1990/2589, art. 2\(a\)\(ii\)](#)
- F19** Sch. 2 Pt. 1 para. 1(b)(c) added by [S.I. 1977/1243, art. 3\(b\)](#)
- F20** Sch. 2 Pt. 1 para. 1(ba) inserted (1.2.2002) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2001 \(S.I. 2001/3932\), art. 2\(2\)](#)
- F21** Sch. 2 Pt. 1 para. 1(d)(e) added by [S.I. 1986/2230, art. 2\(2\)\(b\)](#)

- 2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 above not being dextromethorphan or dextrorphan.
- 3 Any ester or ether of a substance for the time being specified in paragraph 1 or 2 above [<sup>F22</sup>not being a substance for the time being specified in Part II of this Schedule].

#### Textual Amendments

- F22** Words inserted by [S.I. 1973/771, art. 2](#)

- 4 Any salt of a substance for the time being specified in any of paragraphs 1 to 3 above.
- 5 Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 4 above.
- 6 Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1 to 3 of Part II of this Schedule.

**Status:**

Point in time view as at 16/04/2010.

**Changes to legislation:**

There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part I.